Company Overview

BioLife Solutions, Inc. is a U.S.-based biotechnology tools and services company focused on biopreservation media, cell and gene therapy logistics, and cryogenic storage technologies for the biopharmaceutical and regenerative medicine industries. The company primarily serves developers and manufacturers of cell therapies, gene therapies, biologics, and reproductive medicine products. BioLife Solutions operates within the broader life sciences tools and bioprocessing sectors, supplying products and services designed to preserve the viability and stability of biologic materials throughout the manufacturing and distribution process.

The company’s core revenue drivers include proprietary biopreservation media products, automated thawing and storage systems, cold-chain logistics management, and cloud-based tracking solutions used in advanced therapies. BioLife Solutions has developed a specialized position in supporting the commercialization and clinical development of cell and gene therapies, where preservation and transportation conditions are critical to product integrity. Founded in 1987 and headquartered in Bothell, Washington, the company evolved from a preservation media developer into an integrated cell and gene therapy supply-chain platform through internal development and targeted acquisitions.

Business Operations

BioLife Solutions generates revenue through multiple operating activities centered on biopreservation and biostorage technologies. Its principal offerings include the BioLife Biopreservation Media portfolio, automated thawing systems marketed under the ThawSTAR platform, cryogenic storage technologies associated with Sexton Biotechnologies, and cold-chain management software and services from SciSafe and former logistics-related acquisitions. These products are used by biotechnology companies, contract development and manufacturing organizations (CDMOs), research institutions, and healthcare providers involved in advanced biologics manufacturing.

The company operates primarily in the United States but maintains commercial relationships across North America, Europe, and the Asia-Pacific region. BioLife Solutions controls proprietary intellectual property related to cryopreservation formulations and automated thawing technologies, while also operating biostorage and laboratory service facilities through subsidiaries. Strategic acquisitions expanded the company’s operational footprint and technical capabilities, including the acquisitions of Sexton Biotechnologies, SciSafe Holdings, and Custom Biogenic Systems (CBS). The company has also maintained collaborative relationships with therapy developers and bioprocessing firms to integrate its technologies into clinical and commercial manufacturing workflows.

Strategic Position & Investments

BioLife Solutions has positioned itself as an enabling infrastructure provider for the growing cell and gene therapy market. Its strategy has focused on building an end-to-end platform spanning preservation media, cryogenic storage, thawing automation, and biologic material logistics. Management has emphasized recurring revenue generation through consumables and services tied to long-term clinical and commercial therapy production programs. The company has also sought to diversify beyond preservation media into integrated supply-chain technologies supporting advanced therapies.

Major investments and acquisitions have played a central role in this strategy. The acquisition of SciSafe expanded the company into biostorage and laboratory services, while Sexton Biotechnologies added cell processing and cryogenic consumables capabilities. The acquisition of Custom Biogenic Systems (CBS) strengthened BioLife’s controlled-rate freezer and cryogenic equipment portfolio. The company has also invested in cloud-based monitoring and transportation management technologies to support temperature-sensitive biologic products. BioLife Solutions remains active in sectors linked to regenerative medicine, immunotherapy manufacturing, and advanced biologics preservation technologies.

Geographic Footprint

BioLife Solutions is headquartered in Bothell, Washington, and operates primarily within the United States, while maintaining commercial reach across multiple international markets. Its customer base includes biotechnology and pharmaceutical organizations in North America, Europe, and parts of the Asia-Pacific region. International activity largely occurs through product distribution, biostorage services, and partnerships with global therapy developers and manufacturing organizations.

The company’s technologies are used in clinical and commercial programs worldwide, particularly in regions with expanding cell and gene therapy infrastructure. Through subsidiaries and acquired businesses, BioLife Solutions has established operational capabilities related to cryogenic storage, biologics handling, and cold-chain support that extend beyond domestic markets. Public filings and investor disclosures indicate that international demand represents a meaningful component of the company’s commercial strategy, although the majority of operational infrastructure remains U.S.-based.

Leadership & Governance

BioLife Solutions is led by an executive team with backgrounds in biotechnology, medical devices, and life sciences operations. The company’s leadership strategy has emphasized disciplined acquisition integration, expansion within the cell and gene therapy ecosystem, and development of recurring revenue streams tied to biologics manufacturing workflows. Governance oversight is provided through a board of directors and executive leadership structure consistent with publicly traded U.S. biotechnology suppliers.

Key executives and leaders include:

• Roderick de Greef – Chairman and Chief Executive Officer
• Troy Wichterman – Chief Financial Officer
• Sarah Aebersold – Chief Human Resources Officer
• Karen Foster – Chief Quality Officer
• Mike Rice – Chief Commercial Officer

The company’s leadership has consistently communicated a strategic focus on serving the expanding advanced therapy market through integrated preservation, storage, and logistics technologies. Public disclosures, including SEC filings, earnings materials, and investor presentations, indicate that management prioritizes operational scalability, targeted acquisitions, and long-term partnerships with therapy developers and biopharmaceutical manufacturers.